Research to Focus on Neuro-Rehabilitation and Gait Training
Among Stroke Population
Ekso Bionics Holdings, Inc. (OTCQB:EKSO), a robotic exoskeleton
company, announced today that Kessler Foundation, a global leader
in rehabilitation research, has purchased a second exoskeleton, the
Ekso GT, to be used in a new study examining the effectiveness of
wearable robots for neuro-rehabilitation and gait training. Kessler
Foundation is one of the first organizations to integrate the most
recent evolution of this technology, which will be used solely to
study its efficacy for patients with hemiparesis who are less than
three months post-stroke.
Karen Nolan, PhD, research scientist in Human Performance &
Engineering Research and Mooyeon Oh-Park, MD, assistant director of
Stroke Rehabilitation Research for Kessler Foundation, are in
charge of the pilot study. The study plans to enroll 10 stroke
inpatients from Kessler Institute for Rehabilitation to study
patterns of mobility and gait parameters before using Ekso GT,
during use and after use. They will measure several items including
spasticity, range of motion and levels of assistance required in
adults 18-75 years old.
"We're seeing that robotics in rehabilitation are having an
increasingly positive impact on patient outcomes, and research such
as this is key to furthering such progress," said Rodger DeRose,
president and CEO of Kessler Foundation. "Exploring Ekso GT in the
stroke population is an exciting new avenue for our mobility
researchers."
Kessler Foundation has used Ekso Bionics' previous generation
exoskeleton for clinical research in patients with spinal cord
injury since October 2011. Melissa Pullia, PT, ATP, clinical
manager for Ekso Bionics, will work with Kessler's clinical team to
integrate the newest device by training their physical therapists
and researchers on new technology features which provide utility
and efficacy specifically for stroke survivors. Today marks the
completion of the first round of training, an additional week of
comprehensive training will commence in May.
"We're proud of the success Kessler has achieved with use of
their Ekso among their patients with spinal cord injuries over the
last two years," said Melissa. "Continuing to build on their
clinical program by bringing Ekso to their stroke population is
exciting. There have been notable preliminary findings and we are
looking forward to helping them collect the data to quantify
them."
Ekso Bionics designs, develops, and commercializes exoskeletons,
or wearable robots, which have a variety of applications in the
medical, military, industrial, and consumer markets. Exoskeletons
are ready-to-wear, battery-powered robots that are strapped over
the user's clothing, enabling individuals to achieve mobility,
strength, and endurance not otherwise possible. Ekso Bionics' lead
product, EksoTM, is a wearable bionics suit that enables
individuals with any amount of lower extremity weakness to stand up
and walk over ground. Ekso is forging a new frontier in
rehabilitation for people living with the consequences of stroke,
spinal cord injury and other neurological conditions affecting
gait.
About Ekso Bionics
Since 2005, Ekso Bionics has been pioneering the field of
robotic exoskeletons, or wearable robots, to augment human
strength, endurance and mobility. The company's first commercially
available product called Ekso has helped thousands of people living
with paralysis take millions of steps not otherwise possible. By
designing and creating some of the most forward-thinking and
innovative solutions for people looking to augment human
capabilities, Ekso Bionics is helping people rethink current
physical limitations and achieve the remarkable.
Ekso Bionics is headquartered in Richmond, CA and is listed on
the OTC QB under the symbol EKSO. To learn more about Ekso Bionics
please visit us at www.eksobionics.com
Facebook: www.facebook.com/eksobionics Twitter: @eksobionics
YouTube: http://www.youtube.com/user/EksoBionics/
Forward-Looking Statements
Any statements contained in this press release that do not
describe historical facts may constitute forward-looking
statements. Forward-looking statements may include, without
limitation, statements regarding (i) the plans and objectives of
management for future operations, including plans or objectives
relating to the design, development and commercialization of human
exoskeletons, (ii) a projection of income (including income/loss),
earnings (including earnings/loss) per share, capital expenditures,
dividends, capital structure or other financial items, (iii) the
Company's future financial performance and (iv) the assumptions
underlying or relating to any statement described in points (i),
(ii) or (iii) above. Such forward-looking statements are not meant
to predict or guarantee actual results, performance, events or
circumstances and may not be realized because they are based upon
the Company's current projections, plans, objectives, beliefs,
expectations, estimates and assumptions and are subject to a number
of risks and uncertainties and other influences, many of which the
Company has no control over. Actual results and the timing of
certain events and circumstances may differ materially from those
described by the forward-looking statements as a result of these
risks and uncertainties. Factors that may influence or
contribute to the inaccuracy of the forward-looking statements or
cause actual results to differ materially from expected or desired
results may include, without limitation, the Company's inability to
obtain adequate financing, the significant length of time and
resources associated with the development of our products and
related insufficient cash flows and resulting illiquidity, the
Company's inability to expand the Company's business, significant
government regulation of medical devices and the healthcare
industry, lack of product diversification, volatility in the price
of the Company's raw materials, existing or increased competition,
results of arbitration and litigation, stock volatility and
illiquidity, and the Company's failure to implement the Company's
business plans or strategies. These and other factors are
identified and described in more detail in the Company's filings
with the SEC, including, the Company's Current Report on Form 8-K
filed on January 23, 2014. The Company does not undertake to
update these forward-looking statements.
CONTACT: Media Contact:
Heidi Darling, Marketing Manager
Phone: 415.302.4777
hdarling@eksobionics.com
Investor Contact:
Lauren Glaser, Vice President
Phone: 646.378.2972
lglaser@troutgroup.com
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From Sep 2023 to Sep 2024